Aurinia Pharmaceuticals Inc (AUPH)

[Whalatane]

You can do an easy Google search
Normal eGFR level for women between ages 30-35 ( mean age in A-2 ) A2 was around 80% female

Above from memory of the CC details

Voc did improve eGFR ( kidney function ) by around 3 pts over 3 yrs at a cost of around $270k per patient

Their mean eGFR’s were around 78 -80 .. obviously significantly below that of normal women of similar age

Where Voc has a role is in treating severe LN or trying to reverse sudden drop in eGFR … but doubt it will replace current treatment
Voc may allow significant tapering of steroid use which is a plus … but doesn’t seem to eliminate the need for them

Kiwi